Wired News – MabVax Therapeutics Completes Enrollment and Initial Patient Dosing in Expanded Cohort of the Phase-1 Trial Evaluating MVT-5873

LONDON, UK / ACCESSWIRE / December 22, 2017 / Active-Investors.com has just released a free research report on MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX) (“MabVax”). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=MBVX. On December 20, 2017, MabVax, a clinical-stage biotechnology company that works towards the development of antibody-based products to address unmet medical needs in the treatment of cancer, shared that it has completed the enrollment and initial patient dosing in an expanded cohort of its Phase-1 trial for evaluating MVT-5873 in combination with standard of care chemotherapy in newly diagnosed patients with pancreatic and other CA19-9 positive malignancies. Register today and get access to over 1000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, MabVax Therapeutics most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=MBVX

About MV-5873

MabVax’s antibody MVT-5873 is a fully human IgG1 monoclonal antibody (mAb) that targets sialyl Lewis A (sLea), an epitope on CA19-9. CA19-9 is expressed in more than 90% of pancreatic cancers and in other diseases including small cell lung and GI cancers. It plays an important role in tumor adhesion as well as metastasis, and it is a marker of an aggressive cancer phenotype. In fact, CA19-9 serum levels are known to be a valuable adjunct in the diagnosis, prognosis and treatment monitoring of pancreatic cancer.

At present, MVT-5873 is amidst its Phase-1 clinical trials as a therapeutic agent for patients with pancreatic cancer and other CA19-9 positive tumors.

About the Trial

The second portion of MabVax Phase-1 clinical trial for MV-5873 is an open-label, multi-center nonrandomized dose escalation study that aims to evaluate the safety and maximum tolerated dose and recommended Phase-2 dose of MVT-5873 in combination with a standard of care chemotherapy in subjects with pancreatic and other CA19-9 positive malignancies.

Its secondary objectives comprise evaluation of tumor response rate by RECIST 1.1, duration of response, and determination of pharmacokinetics.

Dr. Eileen O’Reilly, Associate Director of the David M. Rubenstein Center for Pancreatic Cancer Research, attending physician, member at Memorial Sloan Kettering Cancer Center and Professor of Medicine at Weill Cornell Medical College, is serving as the lead investigator in the MVT-5873 Phase-1 clinical trial.

The Company intends to report interim safety and RECIST results from the Phase-1 Trial in the first quarter of 2018.

MVT-5873 Demonstrated Positive Performance, In Combination with Nab-paclitaxel and Gemcitabine

Previously, MabVax had shared an update about MVT-5873 at the AACR-NCI-EORTC International Conference in October 2017. It demonstrated encouraging preliminary tumor response data when MVT-5873 was given in combination with nab-paclitaxel and gemcitabine in newly diagnosed patients with CA19-9 positive pancreatic cancer.

The Company revealed that this combination dose was generally well tolerated in all subjects and that two of three subjects receiving 0.125 mg/kg MVT-5873 in combination with gemcitabine plus nab-paclitaxel had a partial response.

Post that, MabVax decided to expand this cohort to further explore safety and potential response.

And now the Company has declared that it has completed the patient enrollment for the 0.125-mg/kg-expansion cohort.

Stock Performance Snapshot

December 21, 2017 – At Thursday’s closing bell, MabVax’s stock dropped 1.30%, ending the trading session at $0.82.

Volume traded for the day: 60.71 thousand shares.

Stock performance in the last month – up 15.62%; and previous three-month period – up 22.41%

After yesterday’s close, MabVax’s market cap was at $17.12 million.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry. This sector was up 0.1% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charter-holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 484837